Researchers analyze switching to Kesimpta from oral therapies Injecting Kesimpta resulted in less disease activity than oral therapies in relapsing MS
People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial.
The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such as Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), or Bafiertam (monomethyl fumarate). After switching to Kesimpta, patients experienced significantly fewer relapses and had less lesions, and few experienced confirmed disability progression over more than one year. These findings “suggest that patients with breakthrough disease with fingolimod or fumarate-based therapies could benefit from switching” to Kesimpta, researchers wrote.
https://multiplesclerosisnewstoday.c...itch-kesimpta/
People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial.
The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such as Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), or Bafiertam (monomethyl fumarate). After switching to Kesimpta, patients experienced significantly fewer relapses and had less lesions, and few experienced confirmed disability progression over more than one year. These findings “suggest that patients with breakthrough disease with fingolimod or fumarate-based therapies could benefit from switching” to Kesimpta, researchers wrote.
https://multiplesclerosisnewstoday.c...itch-kesimpta/